Levigy

Levigy is a Seattle-based biotechnology company dedicated to developing next-generation targeted therapies for cancer, with a primary focus on antibody-drug conjugates (ADCs). The company was founded by a team of seasoned industry executives, including Clay Siegall, the former CEO and founder of Seagen, and Roger Dansey, former Chief Medical Officer of Seagen and Merck. Levigy aims to utilize its leadership's extensive experience in oncology drug development to create innovative treatments that improve outcomes for patients with solid tumors and hematologic malignancies. Currently in the pre-clinical stage, the company is building a robust pipeline of proprietary candidates supported by significant private investment. The firm's strategy involves leveraging advanced linker and payload technologies to enhance the therapeutic index of its ADC candidates.